Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Tavanta Therapeutics

Ownership
Private
Therapeutic Areas
GastroenterologyPulmonologyImmunologyOncologyRare DiseasesNeurology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesTherapeutic peptides

Tavanta Therapeutics General Information

Tavanta has reported positive top-line results from its pivotal Phase III clinical trial for TAVT-45 (abiraterone acetate), which met its primary objective of establishing therapeutic equivalence to Zytiga® in patients with metastatic castrate-resistant prostate cancer and metastatic high-risk castrate-sensitive prostate cancer, with a comparable safety profile.

Contact Information

Website
https://www.tavanta.com/
Primary Industry
Biotech
Corporate Office
Media, Pennsylvania
United States

Drug Pipeline

TAVT-135
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Tavanta Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Tavanta Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Tavanta Therapeutics's complete valuation and funding history, request access »

Tavanta Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals